Last reviewed · How we verify
Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy
A single center, randomized controlled trial design was used to select patients with chronic hepatitis B in the immune control period (HBsAg positive, HBeAg negative, normal ALT, HBsAg ≤ 1500iu/ml, HBV DNA ≤ 2000iu/ml) to enter the study, and to compare the feasibility, effectiveness and safety of pegylate combined with Granulocyte-macrophage colony stimulating factor, high-dose hepatitis B vaccine and pegylate monotherapy in the treatment of patients with chronic hepatitis B in the immune control period
Details
| Lead sponsor | Henan Provincial People's Hospital |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 33 |
| Start date | Fri Dec 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Dec 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Chronic Hepatitis B
Interventions
- PegIFN α- 2b
Countries
China